DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.

Revenue
+11.2%
EPS
+0.58%
Free cash flow
−52.9%
Total debt
+0.31%

Quarter to September 2026, against a year earlier

79.50 4.96 −5.87%
Market cap
$31.5B
P/E
30.6×
Fwd P/E
31.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a

DexCom, Inc. 10-Q filed Oct 29, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 5:22 PM ET · Document on sec.gov · Filing index

What changed

Part II, Item 1A, Risk Factors, against the 10-Q filed Jul 30, 2026: 2 modified; 1 with only figures updated

2 more changes in this Item, word by word, in Powerpack.